Trial Profile

A Phase I clinical trial of Fibroblast growth factor 1 in patients with Parkinson's disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fibroblast growth factor 1 (Primary)
Indications Parkinson's disease
Focus Adverse reactions

Most Recent Events

08 Jun 2022 According to an Zhittya Genesis Medicine media release, the company plans to start this trial within two years.
20 Jan 2020 New trial record
15 Jan 2020 According to an Zhittya Genesis Medicine media release, the company has filed an Investigational New Drug (IND) application with the US FDA to advance its drug into a Phase I clinical trial in patients with Parkinson's disease.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com